estradiol/norethindrone acetate
ACTIVELLA (estradiol/norethindrone acetate) is estrogen receptor agonists [moa]. First approved in 1998.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
ACTIVELLA is an oral combination hormone replacement therapy containing estradiol and norethindrone acetate, indicated for menopausal symptom relief in women. It works as an estrogen receptor agonist, addressing vasomotor and other menopause-related symptoms. The product is a small-molecule tablet approved in 1998.
Product approaching loss of exclusivity with modest Part D spending signals a mature brand likely operating with lean commercial infrastructure and focused cost management.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moACTIVELLA offers limited career growth given its approaching LOE and modest spending profile ($125K Part D). Roles tend to focus on commercial optimization, managed care negotiations, and defensive market positioning rather than expansion or innovation. This is a consolidation-stage product suited for professionals managing mature portfolios or transitioning to specialty women's health roles.